Page last updated: 2024-08-24

halofuginone and Bone Loss, Osteoclastic

halofuginone has been researched along with Bone Loss, Osteoclastic in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bian, Q; Cao, X; Crane, J; Cui, Z; Ding, S; Jin, X; Li, C; Qiu, T; Wan, M; Wang, L; Xie, H; Xie, L; Xie, M; Yu, B; Zhen, G1
Deselm, CJ; Teitelbaum, SL; Zou, W1

Other Studies

2 other study(ies) available for halofuginone and Bone Loss, Osteoclastic

ArticleYear
Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:9

    Topics: Animals; Anterior Cruciate Ligament; Bone and Bones; Bone Remodeling; Bone Resorption; Cartilage, Articular; Disease Models, Animal; Disease Progression; Male; Mice; Mice, Inbred C57BL; Osteoarthritis; Osteoclasts; Piperidines; Quinazolinones; Random Allocation; Rats; Rats, Inbred Lew; Transforming Growth Factor beta

2016
Halofuginone prevents estrogen-deficient osteoporosis in mice.
    Journal of cellular biochemistry, 2012, Volume: 113, Issue:10

    Topics: Animals; Body Weight; Bone Density Conservation Agents; Bone Resorption; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Evaluation, Preclinical; Estrogens; Interleukin-17; Mice; Osteoclasts; Osteogenesis; Osteoporosis; Ovariectomy; Piperidines; Quinazolinones; RANK Ligand

2012